Description

Learning ObjectivesAt the end of this module, the attendees will:Be aware of current theories of the causes and neurochemistry of schizophreniaKnow the pharmacology of conventional and atypical drugsBe aware of the clinical assessment of therapeutic and adverse effectsHave an opinion about relative benefits of conventional and atypical drugsBe updated on guidelines and the social context of drug prescribing in schizophreniaHave had an opportunity to discuss difficult management problems with colleagues and expertsThis module is eligible for 11 CPD hours which are subject to peer group review.For further details contact Susan Chandler, BAP Executive Officer: susan@bap.org.uk